The corona vaccine from the American pharmaceutical company Novavax can be marketed and used in the EU. The European Commission approves the EU market authorization of the vaccine under Nuvaxovid.
It will be the fifth vaccine to protect EU citizens from Covid-19, as recommended by the regulator, the European Medicines Agency (EMA), earlier Monday.
The vaccine is primarily intended for adults. They get two shots three weeks apart. The vaccine has not yet been evaluated for children and booster shots. The committee has already ordered 100 million doses of the drug, with an option for another 100 million doses. According to the usual distribution, the Netherlands would receive 3.89 percent of this.
The other four vaccines authorized in the European Union to date are Pfizer/BioNTech, Moderna, AstraZeneca and Janssen.